-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, PAQ Therapeutics, which is committed to using autophagy to develop innovative methods to treat diseases and improve health, announced the completion of a US$30 million Series A financing
.
The company's technology will expand the therapeutic potential of autophagy, not only to target the degradation of disease-causing proteins, but also to restore health by degrading lipids, pathogens or other target substrates
.
The company's autophagosome-tethering compound (ATTEC) can bind target substrates to autophagosomes, leading to substrate degradation
.
When it comes to autophagy, everyone may be familiar with it.
In 2016, Japanese scientist Yoshinori Ohsumi won the Nobel Prize in Physiology or Medicine for his research on the mechanism of autophagy, and it also made more people know that this is true.
A physiological process ubiquitous in nuclear organisms
.
Autophagy is a physiological process in which cells use lysosomes to degrade and reuse their own components
.
It is mainly used to remove and degrade damaged cell structures, senescent organelles, and biological macromolecules that are no longer needed in cells
.
Autophagy is like a "waste recycling station" in the cell
.
▲Illustration of the autophagy process (picture source: reference [6]) The core technology of PAQ Therapeutics is derived from the breakthrough research of Professor Lu Boxun's group of Fudan University
.
In a study published in Nature in 2019, Professor Lu Boxun’s group developed a bispecific molecule that can bind to a protein called LC3 in autophagosomes on the one hand, and on the other Mutant Huntingtin (mHTT) binding
.
This can pull the mHTT protein into the autophagosome for degradation
.
Such molecules are called autophagosome binding compounds (ATTEC)
.
▲Schematic diagram of the mechanism of action of autophagosome binding compounds (picture source: reference [3]) PAQ will use the ATTEC technology platform to first focus on the development of therapeutics for neurodegenerative diseases, and may expand to a series of other treatment options with limited options Disease
.
The funds obtained from the A round of financing will help the company further promote the development of the ATTEC technology platform and the progress of the R&D pipeline project
.
“PAQ’s expert team is working hard to use powerful autophagy pathways to directly target and eliminate disease-causing substrates
.
” said Dr.
Nan Ji, PAQ co-founder, president and CEO, “and the use of ubiquitin-protease Compared with targeted protein degradation by the body, ATTEC provides a platform based on autophagy, which is complementary and differentiated
.
"Reference: [1] PAQ Therapeutics Launches with $30 Million Series A to Develop Novel Therapies through Autophagy-Dependent Degradation.
Retrieved July 15, 2021, from https:// launches-with-30-million-series-a-to-develop-novel-therapies-through-autophagy-dependent-degradation-301333970.
html[2] This Nobel Prize discovery is providing new weapons for conquering the "king of cancer" .
Retrieved July 15, 2021, fro from https://mp.
weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649983739&idx=1&sn=28f9830c4db32a12a5c24fb62ae0573c[3] Li et al.
, (2020) ATTEC: a potential new approach to target proteinopathies.
Autophagy, https://doi.
org/10.
1080/15548627.
2019.
1688556[4] Li et al.
, (2019) Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds.
Nature, https ://doi.
org/10.
1038/s41586-019-1722-1[5] Small molecule glue that distinguishes mutant from the wild-type HTT protein: potential entry points for Huntington's disease drug discovery.
Retrieved July 15, 2021, from https:// edu.
cn/en/2019/1030/c344a102560/page.
htm[6] WormBook: The Online Review of C.
elegans Biology.
Retrieved May 9, 2019, from https:// books/NBK116074/figure/autophagy_figure1/Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
The company's technology will expand the therapeutic potential of autophagy, not only to target the degradation of disease-causing proteins, but also to restore health by degrading lipids, pathogens or other target substrates
.
The company's autophagosome-tethering compound (ATTEC) can bind target substrates to autophagosomes, leading to substrate degradation
.
When it comes to autophagy, everyone may be familiar with it.
In 2016, Japanese scientist Yoshinori Ohsumi won the Nobel Prize in Physiology or Medicine for his research on the mechanism of autophagy, and it also made more people know that this is true.
A physiological process ubiquitous in nuclear organisms
.
Autophagy is a physiological process in which cells use lysosomes to degrade and reuse their own components
.
It is mainly used to remove and degrade damaged cell structures, senescent organelles, and biological macromolecules that are no longer needed in cells
.
Autophagy is like a "waste recycling station" in the cell
.
▲Illustration of the autophagy process (picture source: reference [6]) The core technology of PAQ Therapeutics is derived from the breakthrough research of Professor Lu Boxun's group of Fudan University
.
In a study published in Nature in 2019, Professor Lu Boxun’s group developed a bispecific molecule that can bind to a protein called LC3 in autophagosomes on the one hand, and on the other Mutant Huntingtin (mHTT) binding
.
This can pull the mHTT protein into the autophagosome for degradation
.
Such molecules are called autophagosome binding compounds (ATTEC)
.
▲Schematic diagram of the mechanism of action of autophagosome binding compounds (picture source: reference [3]) PAQ will use the ATTEC technology platform to first focus on the development of therapeutics for neurodegenerative diseases, and may expand to a series of other treatment options with limited options Disease
.
The funds obtained from the A round of financing will help the company further promote the development of the ATTEC technology platform and the progress of the R&D pipeline project
.
“PAQ’s expert team is working hard to use powerful autophagy pathways to directly target and eliminate disease-causing substrates
.
” said Dr.
Nan Ji, PAQ co-founder, president and CEO, “and the use of ubiquitin-protease Compared with targeted protein degradation by the body, ATTEC provides a platform based on autophagy, which is complementary and differentiated
.
"Reference: [1] PAQ Therapeutics Launches with $30 Million Series A to Develop Novel Therapies through Autophagy-Dependent Degradation.
Retrieved July 15, 2021, from https:// launches-with-30-million-series-a-to-develop-novel-therapies-through-autophagy-dependent-degradation-301333970.
html[2] This Nobel Prize discovery is providing new weapons for conquering the "king of cancer" .
Retrieved July 15, 2021, fro from https://mp.
weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649983739&idx=1&sn=28f9830c4db32a12a5c24fb62ae0573c[3] Li et al.
, (2020) ATTEC: a potential new approach to target proteinopathies.
Autophagy, https://doi.
org/10.
1080/15548627.
2019.
1688556[4] Li et al.
, (2019) Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds.
Nature, https ://doi.
org/10.
1038/s41586-019-1722-1[5] Small molecule glue that distinguishes mutant from the wild-type HTT protein: potential entry points for Huntington's disease drug discovery.
Retrieved July 15, 2021, from https:// edu.
cn/en/2019/1030/c344a102560/page.
htm[6] WormBook: The Online Review of C.
elegans Biology.
Retrieved May 9, 2019, from https:// books/NBK116074/figure/autophagy_figure1/Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
